Improved gastrointestinal symptom burden after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in kidney transplanted children

Pediatric Transplantation

Volumn 12, Issue 6, 2008, Pages 640-642

  Pape, Lars ^a   Ahlenstiel, Thurid ^a   Kreuzer, Martin ^a   Ehrich, Jochen H H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Children; Gastrointestinal side effects; Immunosuppression; Kidney transplantation; Mycophenolate mofetil

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG SUBSTITUTION; ENTERIC COATED TABLET; FEMALE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY TRANSPLANTATION; MALE; RECIPIENT; RISK REDUCTION;

ADOLESCENT; CHILD; CYCLOSPORINE; FEMALE; GASTROINTESTINAL DISEASES; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; PREDNISOLONE; TABLETS, ENTERIC-COATED; TACROLIMUS;

EID: 49349107980     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2007.00831.x     Document Type: Article

References (16)

1. Cecka JM. The UNOS renal transplant registry. Clin Transplant 2001: 1 18.
2. Pape L, Strehlau J, Henne T, et al. Single centre experience with basiliximab in paediatric renal transplantation. Nephrol Dial Transplant 2002: 17: 276 280.
3. Henne T, Latta K, Strehlau J, Pape L, Ehrich JH, Offner G. Mycophenolate mofetil-induced reversal of glomerular filtration loss in children with chronic allograft nephropathy. Transplantation 2003: 76: 1326 1330.
4. Toenshoff B, Hoecker B. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity. Pediatr Transplant 2006: 10: 721 729.
5. Pelletier RP. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Am J Transplant 2002: S3: 467.
6. Chan L, Mulagonkar S, Walker R, Arns W, Ambühl P, Schiavelli R. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2007: 81: 1290 1297.
7. Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant recipients. Am J Transplant 2003: 4: 237.
8. Budde K, Curtis J, Knoll G, et al. Enteric coated mycophenolate sodium TN be safely administered in maintenance renal transplant patients: Results of a 1-year study. Am J Transplant 2003: 4: 237.
9. Revicki DA, Wood M, Wiklund I, Crawley J. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastrointestinal reflux disease. Qual Lifr Res 1998: 7: 75.
10. Svedlund J, Sjodin I, Dotevall G. GSRS - a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988: 33: 129 134.
11. Svedlund J, Sullivan M, Liedman B, Lundell L. Long term consequences of gastrectomy for patient's quality of life: The impact of reconstructive techniques. Am J Gastroentero 1999: 94: 438 445.
12. Filler G, Lepage M. Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula? Pediatr Nephrol 2003: 18: 981 985.
13. Pietruck F, Abbud-Fillho M, Vathsala A, Massari PU, Po-Huang L, Nashan B. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable maintenance renal transplant recipients: Pooled results from three international, multicenter studies. Transpl Proc 2007: 39: 103 111.
14. Nevins TE. Non-compliance and its management in teenagers. Pediatr Transplant 2002: 6: 475 479.
15. Knoll GA, MacDonald I, Khan A, Van Walraven C. Mycophenlate mofetil dose reduction and the risk of acute rejection after renal transplantation. Am J Transplant 2002: 3: 467.
16. Butler JA, Peveler RC, Roderic P, et al. Modifiable risk factors for nonadherence to immunosuppressants in renal transplant recipients: A cross sectional study. Nephrol Dial Transplant 2004: 19: 3144.